US 12,258,576 B2
Cell culture media compositions for primary cells
Allan B. Dietz, Chatfield, MN (US); and Gaylord Knutson, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on May 31, 2017, as Appl. No. 15/609,444.
Application 15/609,444 is a division of application No. 14/712,491, filed on May 14, 2015, granted, now 11,891,620.
Claims priority of provisional application 61/994,637, filed on May 16, 2014.
Prior Publication US 2017/0260496 A1, Sep. 14, 2017
Int. Cl. C12N 5/0775 (2010.01); A61K 35/19 (2015.01); A61P 17/02 (2006.01); C12N 5/00 (2006.01); C12N 5/071 (2010.01)
CPC C12N 5/0037 (2013.01) [A61K 35/19 (2013.01); A61P 17/02 (2018.01); C12N 5/0068 (2013.01); C12N 5/0662 (2013.01); C12N 5/069 (2013.01); C12N 5/0692 (2013.01); C12N 2500/84 (2013.01); C12N 2501/105 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/165 (2013.01); C12N 2502/115 (2013.01); C12N 2533/50 (2013.01); C12N 2533/90 (2013.01)] 16 Claims
 
1. A composition comprising:
a lyophilized platelet lysate (LPL), wherein the LPL is derived from a platelet lysate, prepared by lysing a platelet preparation, and wherein the LPL retains the cell culture growth properties after lyophilization;
a supplemental growth factor, wherein the supplemental growth factor is present in the composition at a ratio of at least 2000 to 1 per ng of FGF in the platelet lysate; and
a physiological carrier, wherein the physiological carrier has a pH of about 5.5-7.5, wherein the composition does not include a bulking agent.